FDA approves Eli Lilly's oral GLP-1 Foundayo for obesity
The orforglipron pill gives Lilly a direct answer to Novo Nordisk's oral semaglutide, the first branded oral GLP-1 on the US obesity market.
DO
By Daniel Okafor · Regulatory Correspondent
Apr 1 03:00 ETSource: Fierce Pharma
The wire
- 01The FDA cleared Lilly's oral GLP-1 Foundayo, according to Fierce Pharma, following Novo Nordisk's earlier oral entry in the obesity category.
- 02A second oral incretin option changes prescribing and supply planning for clinicians and telehealth operators who have relied on injectables.
- 03Label details, pricing and payer coverage will determine how quickly the pill displaces injectable GLP-1 volume.
From the source
Read at fiercepharma.comLilly answers Novo's GLP-1 pill with highly anticipated FDA nod for Foundayo